{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:32:35Z","timestamp":1762428755838,"version":"build-2065373602"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2025.1699044","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:29:04Z","timestamp":1762428544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary: Iridoids derived from Valeriana jatamansi jones alleviates neuroinflammation and blood spinal cord barrier permeability after spinal cord injury by activating the Nrf2\/HO-1 signaling pathway"],"prefix":"10.3389","volume":"16","author":[{"given":"Kai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"856777","DOI":"10.3389\/fphar.2022.856777","article-title":"Berberine attenuates cell motility via inhibiting inflammation-mediated lysyl Hydroxylase-2 and glycolysis","volume":"13","author":"Du","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1597719","DOI":"10.3389\/fphar.2025.1597719","article-title":"Iridoids derived from Valeriana jatamansi jones alleviates neuroinflammation and blood spinal cord barrier permeability after spinal cord injury by activating the Nrf2\/HO-1 signaling pathway","volume":"16","author":"He","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1089\/neu.2020.7413","article-title":"Blood-Spinal cord barrier in spinal cord injury: a review","volume":"38","author":"Jin","year":"2021","journal-title":"J. Neurotrauma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12929-019-0529-6","article-title":"Fibronectin inhibitor pUR4 attenuates tumor necrosis factor \u03b1-induced endothelial hyperpermeability by modulating \u03b21 integrin activation","volume":"26","author":"Lee","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"34720","DOI":"10.1021\/acsnano.4c06030","article-title":"Spatially precise and minimally invasive delivery of peptides to the spinal cord for behavior modulation","volume":"18","author":"Leong","year":"2024","journal-title":"ACS Nano"},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2025.07.024","article-title":"Exercise-preconditioning attenuates TAC-induced cardiac hypertrophy and myocardial injury through activating NRF2","volume":"239","author":"Ni","year":"2025","journal-title":"Free Radic. Biol. and Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12951-024-02737-5","article-title":"Platelet-rich plasma-derived exosomes promote blood-spinal cord barrier repair and attenuate neuroinflammation after spinal cord injury","volume":"22","author":"Nie","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12987-023-00455-0","article-title":"Standardization of TEER measurement for blood-spinal cord barrier models","volume":"20","author":"Santaguida","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-Deficient NSCLC tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem. Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:29:04Z","timestamp":1762428544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":9,"alternative-id":["10.3389\/fphar.2025.1699044"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1699044","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1699044"}}